Moonef Alotaibi1,2, Valeria Valova1, Toni HÄnsel1, Carmen Stromberger3, Grzegorz Kofla4, Heidi Olze1, Iris Piwonski5, Andreas Albers6, Sebastian Ochsenreither7,8, Annekatrin Coordes9. 1. Department of Otorhinolaryngology, Head and Neck Surgery (CVK and CCM), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 2. King Fahad Medical City, Department of Otorhinolaryngology, Head and Neck Surgery, Riyadh, Kingdom of Saudi Arabia. 3. Department of Radiooncology (CVK), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 4. Department of Oncology (CVK), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 5. Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 6. Department of Otorhinolaryngology (CBF), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 7. Department of Oncology (CBF), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 8. Charité Comprehensive Cancer Center, Berlin, Germany. 9. Department of Otorhinolaryngology, Head and Neck Surgery (CVK and CCM), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; annekatrin.coordes@charite.de.
Abstract
BACKGROUND/AIM: High risk Human papillomavirus (hr-HPV) and smoking are independant risk factors for head and neck squamous cell carcinomas (HNSCC). While hr-HPV+ HNSCC has a better prognosis than smoking-associated HNSCC no systematic data are yet available about the combined risk. PATIENTS AND METHODS: We performed a meta-analysis to assess the overall survival of HNSCC patients relative to the hr-HPV and smoking status. A literature review up to November 2019 was conducted in PubMed and Cochrane Library using the search terms 'HPV, Smoking and HNSCC'. RESULTS: Nine out of 748 articles were included, 1,436 out of 2,080 patients were hr-HPV+ The prevalence of hr-HPV+ smokers was 36%. The meta-analysis showed a significantly better 5-year overall survival for HPV+ non-smokers compared to smokers with risk ratio of 1.94 (95% confidence intervaI=1.46-2.58). CONCLUSION: Smoking is a negative prognostic factor for overall survival in patients with hr-HPV+ HNSCC and should thus be an important part of staging and treatment. Copyright
BACKGROUND/AIM: High risk Human papillomavirus (hr-HPV) and smoking are independant risk factors for head and neck squamous cell carcinomas (HNSCC). While hr-HPV+ HNSCC has a better prognosis than smoking-associated HNSCC no systematic data are yet available about the combined risk. PATIENTS AND METHODS: We performed a meta-analysis to assess the overall survival of HNSCC patients relative to the hr-HPV and smoking status. A literature review up to November 2019 was conducted in PubMed and Cochrane Library using the search terms 'HPV, Smoking and HNSCC'. RESULTS: Nine out of 748 articles were included, 1,436 out of 2,080 patients were hr-HPV+ The prevalence of hr-HPV+ smokers was 36%. The meta-analysis showed a significantly better 5-year overall survival for HPV+ non-smokers compared to smokers with risk ratio of 1.94 (95% confidence intervaI=1.46-2.58). CONCLUSION: Smoking is a negative prognostic factor for overall survival in patients with hr-HPV+ HNSCC and should thus be an important part of staging and treatment. Copyright
Authors: Stephanie Y Chen; Sean Massa; Angela L Mazul; Dorina Kallogjeri; Lauren Yaeger; Ryan S Jackson; Jose Zevallos; Patrik Pipkorn Journal: Am J Otolaryngol Date: 2020-06-02 Impact factor: 1.808
Authors: W J Blot; J K McLaughlin; D M Winn; D F Austin; R S Greenberg; S Preston-Martin; L Bernstein; J B Schoenberg; A Stemhagen; J F Fraumeni Journal: Cancer Res Date: 1988-06-01 Impact factor: 12.701
Authors: Hong Li; Sina J Torabi; Wendell G Yarbrough; Saral Mehra; Heather A Osborn; Benjamin Judson Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-06-01 Impact factor: 6.223
Authors: Anvesh R Kompelli; Patrick Morgan; Hong Li; William Harris; Terry A Day; David M Neskey Journal: Otolaryngol Head Neck Surg Date: 2018-12-11 Impact factor: 3.497
Authors: Astrid Billfalk-Kelly; Eugene Yu; Jie Su; Brian O'Sullivan; John Waldron; Jolie Ringash; Eric Bartlett; Bayardo Perez-Ordonez; Ilan Weinreb; Andrew Bayley; Scott V Bratman; John Cho; Meredith Giuliani; Andrew Hope; Ali Hosni; John Kim; Aaron R Hansen; John de Almeida; Li Tong; Wei Xu; Shao Hui Huang Journal: Int J Radiat Oncol Biol Phys Date: 2019-04-04 Impact factor: 7.038
Authors: Christian A Maino Vieytes; Sandra L Rodriguez-Zas; Zeynep Madak-Erdogan; Rebecca L Smith; Katie R Zarins; Gregory T Wolf; Laura S Rozek; Alison M Mondul; Anna E Arthur Journal: Front Nutr Date: 2022-04-25